Interv Akut Kardiol 2011; 10(5-6): 210

Novinky v antikoagulační léčbě fibrilace síní

Jan Vojáček
1. interní kardioangiologická klinika LF UK a FN, Hradec Králové

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vojáček J. Novinky v antikoagulační léčbě fibrilace síní. Interv Akut Kardiol. 2011;10(5-6):210.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vojáček J, Miklošová M, Ševčíková H, Ševčík R. Antitrombotická léčba a její klinické monitorování - pohled kardiologa. Transfuze a hematologie dnes, 2010; 16(Suppl 4): 26-28. ISSN 1213-5763.
    2. Höchtl T, Huber K. New anticoagulants for the prevention of stroke in atrial fibrillation. Fundam Clin Pharmacol. 2011; 10(1111): 1472-8206. 2011.00982.x. [Epub ahead of print].
    3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151. Epub 2009 Aug 30. Go to original source... Go to PubMed...
    4. Vojáček J. The results of the RE-LY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation. Vnitr Lek. 2009; 55(11): 1085-1088. Go to PubMed...
    5. Ingelmo C, Wazni O. Review of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial: Warfarin Versus Dabigatran. Curr Cardiol Rep. 201; 13(5): 357-360. Go to PubMed...
    6. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-91. Epub 2011 Aug 10. Go to original source... Go to PubMed...
    7. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-992. Epub 2011 Aug 27. Go to original source... Go to PubMed...
    8. Boehringer Ingelheim. Průlomová léčba pacientů s fibrilací síní PRADAXA(R) (dabigatran etexilát) - po více než 50 letech první lék schválený v Evropě pro prevenci cévních mozkových příhod u pacientů s fibrilací síní. Tisková zpráva.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.